Search

Your search keyword '"CARDOSO, FATIMA"' showing total 1,540 results
Start Over Author "CARDOSO, FATIMA"
1,540 results on '"CARDOSO, FATIMA"'

1. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

Author

Vaz, Sofia C., Woll, John Patrick Pilkington, Cardoso, Fatima, Groheux, David, Cook, Gary J. R., Ulaner, Gary A., Jacene, Heather, Rubio, Isabel T., Schoones, Jan W., Peeters, Marie-Jeanne Vrancken, Poortmans, Philip, Mann, Ritse M., Graff, Stephanie L., Dibble, Elizabeth H., and de Geus-Oei, Lioe-Fee

Published
2024
Full Text
View/download PDF

3. Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.

Author

Cardoso, Fatima, Rihani, Julie, Harmer, Victoria, Harbeck, Nadia, Casas, Ana, Fasching, Peter, Moore, Adam, de Courcy, Joanna, Pathak, Purnima, Haftchenary, Sina, Aubel, Dawn, Schumacher-Wulf, Eva, and Rugo, Hope

Subjects
advanced breast cancer, physician/patient communication, qualitative research, quality of life, survey, Humans, Female, Quality of Life, Breast Neoplasms, Cross-Sectional Studies, Sleep Initiation and Maintenance Disorders, Surveys and Questionnaires, Drug-Related Side Effects and Adverse Reactions, Back Pain, Fatigue, Diarrhea
Abstract

BACKGROUND: Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals (HCPs) and patients perspectives on the importance of QOL discussions and the impact of SEs on QOL in clinical settings. PATIENTS AND METHODS: A cross-sectional online survey was conducted (7/2020-5/2021) among oncologists, nurses, and patients with HR+/HER2- ABC in 7 countries. RESULTS: The survey was completed by 502 HCPs and 467 patients. Overall, 88% of oncologists and 49% of patients recalled QOL discussions at follow-up. In the first- through fourth-line (1L, 2L, 3L, and 4L) settings, respectively, 48%, 57%, 79%, and 85% of oncologists reported QOL was very important; 73% and 45% of patients receiving 1L and 2L treatment and 40% receiving 3L+ treatment indicated QOL was important. Patients reported that insomnia, anxiety, back pain, fatigue, diarrhea, hot flashes, low sexual interest, and loss of appetite had a moderate/severe impact on QOL. Of patients experiencing certain SEs, ≥64% did not discuss them with HCPs until there was a moderate/severe impact on QOL. In patients receiving a CDK4/6 inhibitor, SEs, including insomnia, diarrhea, back pain, and fatigue, had a moderate/severe impact on QOL. CONCLUSIONS: This survey discovered disconnects between HCPs and patients with ABC on the importance of QOL discussions and the impact of SEs on QOL. These data support the use of ABC-specific QOL questionnaires that closely monitor SEs impacting QOL.

Published
2023

4. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Author

Lopes Cardozo, Josephine MN, Andrulis, Irene L, Bojesen, Stig E, Dörk, Thilo, Eccles, Diana M, Fasching, Peter A, Hooning, Maartje J, Keeman, Renske, Nevanlinna, Heli, Rutgers, Emiel JT, Easton, Douglas F, Hall, Per, Pharoah, Paul DP, van 't Veer, Laura J, Schmidt, Marjanka K, Ahearn, Thomas U, Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L, Augustinsson, Annelie, Beane Freeman, Laura E, Becher, Heiko, Beckmann, Matthias W, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bolla, Manjeet K, Bonanni, Bernardo, Boyle, Terry, Brenner, Hermann, Brucker, Sara Y, Brüning, Thomas, Burwinkel, Barbara, Buys, Saundra S, Camp, Nicola J, Canzian, Federico, Cardoso, Fatima, Castelao, Jose E, Cessna, Melissa H, Chan, Tsun L, Chang-Claude, Jenny, Chenevix-Trench, Georgia, Choi, Ji-Yeob, Colonna, Sarah V, Copson, Ellen, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Daly, Mary B, Dennis, Joe, Devilee, Peter, Drukker, Caroline A, Dunning, Alison M, Dwek, Miriam, Eliassen, A Heather, Engel, Christoph, Evans, D Gareth, Figueroa, Jonine D, Fletcher, Olivia, Flyger, Henrik, Gago-Dominguez, Manuela, García-Closas, Montserrat, García-Sáenz, José A, Genkinger, Jeanine, Giles, Graham G, González-Neira, Anna, Guénel, Pascal, Gündert, Melanie, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hamann, Ute, Hartman, Mikael, Heemskerk-Gerritsen, Bernadette AM, Hein, Alexander, Ho, Weang-Kee, Hoppe, Reiner, Hopper, John L, Houlston, Richard S, Howell, Anthony, Hunter, David J, Ito, Hidemi, Jakubowska, Anna, Jernström, Helena, John, Esther M, Johnson, Nichola, Jones, Michael E, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Kim, Sung-Won, Kitahara, Cari M, Koppert, Linetta B, Kosma, Veli-Matti, Kraft, Peter, Kristensen, Vessela N, Kubelka-Sabit, Katerina, and Koutros, Stella

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer, Good Health and Well Being, Female, Humans, Breast Neoplasms, Risk Factors, Prognosis, Proportional Hazards Models, Breast, Breast Cancer Association Consortium and MINDACT Collaborators, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeA polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer.MethodsWomen with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.ResultsThe PRS313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent.ConclusionAn increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.

Published
2023

5. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Author

Rugo, Hope S, Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D, Bachelot, Thomas, Wright, Gail S, Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N, Pluard, Timothy J, Ricci, Francesco, Gwin, William R, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A, Freedman, Orit, Jakobsen, Erik H, Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A, Kaufman, Peter A, Ashley, Emily J, Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J, and Group, on behalf of the SOPHIA Study

Subjects
Cancer, Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Female, Trastuzumab, Breast Neoplasms, Receptor, ErbB-2, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, SOPHIA Study Group, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer, is reported with updated safety. Overall, 536 patients in the intention-to-treat population were randomly assigned to margetuximab (15 mg/kg intravenously once every 3 weeks; n = 266) plus chemotherapy or trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg; n = 270) plus chemotherapy. Primary end points were progression-free survival, previously reported, and OS. Final OS analysis was triggered by 385 prespecified events. The median OS was 21.6 months (95% CI, 18.89 to 25.07) with margetuximab versus 21.9 months (95% CI, 18.69 to 24.18) with trastuzumab (hazard ratio [HR], 0.95; 95% CI, 0.77 to 1.17; P = .620). Preplanned, exploratory analysis of CD16A genotyping suggested a possible improvement in OS for margetuximab in CD16A-158FF patients versus trastuzumab (median OS, 23.6 v 19.2 months; HR, 0.72; 95% CI, 0.52 to 1.00) and a possible improvement in OS for trastuzumab in CD16A-158VV patients versus margetuximab (median OS, 31.1 v 22.0 months; HR, 1.77; 95% CI, 1.01 to 3.12). Margetuximab safety was comparable with trastuzumab. Final overall OS analysis did not demonstrate margetuximab advantage over trastuzumab. Margetuximab studies in patients with human epidermal growth factor receptor 2-positive breast cancer with different CD16A allelic variants are warranted.

Published
2023

6. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

Author

Rugo, Hope S, Harmer, Victoria, O’Shaughnessy, Joyce, Jhaveri, Komal, Tolaney, Sara M, Cardoso, Fatima, Bardia, Aditya, Maheshwari, Vikalp Kumar, Tripathi, Sandeep, Haftchenary, Sina, Pathak, Purnima, and Fasching, Peter A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, abemaciclib, CDK4, inhibitor, MONALEESA-2, MONARCH 3, quality of life, ribociclib, CDK4/6 inhibitor, Oncology and carcinogenesis
Abstract

BackgroundA cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that affects treatment decisions. Understanding the relevance of CDK4/6i treatment on QoL is gaining importance given use in earlier treatment lines for ABC and an emerging role in treating early breast cancer in which QoL may be more impactful. In the absence of head-to-head trial data, a matching-adjusted indirect comparison (MAIC) permits comparative efficacy between trials.ObjectiveIn this analysis, patient-reported QoL for MONALEESA-2 [ribociclib + aromatase inhibitor (AI)] and MONARCH 3 (abemaciclib + AI) was compared using MAIC with a focus on individual domains.DesignAn anchored MAIC of QoL comparing ribociclib + AI versus abemaciclib + AI was performed using data from the European Organization for Research and Treatment of Cancer quality of life questionnaire (QLQ)-C30 and BR-23 questionnaires.MethodsIndividual patient data from MONALEESA-2 and published aggregated data from MONARCH 3 were included in this analysis. Time to sustained deterioration (TTSD) was calculated as the time from randomization to a ⩾10-point deterioration with no later improvement above this threshold.ResultsPatients from the ribociclib (n = 205) and placebo (n = 149) arms of MONALEESA-2 were matched with patients from the abemaciclib (n = 328) and placebo (n = 165) arms of MONARCH 3. After weighting, baseline patient characteristics were well balanced. TTSD significantly favored ribociclib versus abemaciclib in appetite loss [hazard ratio (HR), 0.46; 95% confidence interval (CI), 0.27-0.81], diarrhea (HR, 0.42; 95% CI, 0.23-0.79), fatigue (HR, 0.63; 95% CI, 0.41-0.96), and arm symptoms (HR, 0.49; 95% CI, 0.30-0.79). TTSD did not significantly favor abemaciclib compared with ribociclib in any functional or symptom scale of the QLQ-C30 or BR-23 questionnaires.ConclusionsThis MAIC indicates that ribociclib + AI is associated with better symptom-related QoL than abemaciclib + AI for postmenopausal patients with HR+/HER2- ABC treated in the first-line setting.Trial registrationNCT01958021 (MONALEESA-2) and NCT02246621 (MONARCH 3).

Published
2023

9. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Author

Cardoso, Fatima, Paluch-Shimon, Shani, Schumacher-Wulf, Eva, Matos, Leonor, Gelmon, Karen, Aapro, Matti S., Bajpai, Jyoti, Barrios, Carlos H., Bergh, Jonas, Bergsten-Nordström, Elizabeth, Biganzoli, Laura, Cardoso, Maria João, Carey, Lisa A., Chavez-MacGregor, Mariana, Chidebe, Runcie, Cortés, Javier, Curigliano, Giuseppe, Dent, Rebecca A., El Saghir, Nagi S., Eniu, Alexandru, Fallowfield, Lesley, Francis, Prudence A., Franco Millan, Sandra X., Gilchrist, Jenny, Gligorov, Joseph, Gradishar, William J., Haidinger, Renate, Harbeck, Nadia, Hu, Xichun, Kaur, Ranjit, Kiely, Belinda, Kim, Sung-Bae, Koppikar, Smruti, Kuper-Hommel, Marion J.J., Lecouvet, Frédéric E., Mason, Ginny, Mertz, Shirley A., Mueller, Volkmar, Myerson, Claire, Neciosup, Silvia, Offersen, Birgitte V., Ohno, Shinji, Pagani, Olivia, Partridge, Ann H., Penault-Llorca, Frédérique, Prat, Aleix, Rugo, Hope S., Senkus, Elzbieta, Sledge, George W., Swain, Sandra M., Thomssen, Christoph, Vorobiof, Daniel A., Vuylsteke, Peter, Wiseman, Theresa, Xu, Binghe, Costa, Alberto, Norton, Larry, and Winer, Eric P.

Published
2024
Full Text
View/download PDF

11. Obesity-associated changes in molecular biology of primary breast cancer

Author

Nguyen, Ha-Linh, Geukens, Tatjana, Maetens, Marion, Aparicio, Samuel, Bassez, Ayse, Borg, Ake, Brock, Jane, Broeks, Annegien, Caldas, Carlos, Cardoso, Fatima, De Schepper, Maxim, Delorenzi, Mauro, Drukker, Caroline A., Glas, Annuska M., Green, Andrew R., Isnaldi, Edoardo, Eyfjörð, Jórunn, Khout, Hazem, Knappskog, Stian, Krishnamurthy, Savitri, Lakhani, Sunil R., Langerod, Anita, Martens, John W. M., McCart Reed, Amy E., Murphy, Leigh, Naulaerts, Stefan, Nik-Zainal, Serena, Nevelsteen, Ines, Neven, Patrick, Piccart, Martine, Poncet, Coralie, Punie, Kevin, Purdie, Colin, Rakha, Emad A., Richardson, Andrea, Rutgers, Emiel, Vincent-Salomon, Anne, Simpson, Peter T., Schmidt, Marjanka K., Sotiriou, Christos, Span, Paul N., Tan, Kiat Tee Benita, Thompson, Alastair, Tommasi, Stefania, Van Baelen, Karen, Van de Vijver, Marc, Van Laere, Steven, van’t Veer, Laura, Viale, Giuseppe, Viari, Alain, Vos, Hanne, Witteveen, Anke T., Wildiers, Hans, Floris, Giuseppe, Garg, Abhishek D., Smeets, Ann, Lambrechts, Diether, Biganzoli, Elia, Richard, François, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

13. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Author

Lu, Yen-Shen, Im, Seock-Ah, Colleoni, Marco, Franke, Fabio, Bardia, Aditya, Cardoso, Fatima, Harbeck, Nadia, Hurvitz, Sara, Chow, Louis, Sohn, Joohyuk, Lee, Keun Seok, Campos-Gomez, Saul, Vazquez, Rafael Villanueva, Jung, Kyung Hae, Babu, K Govind, Wheatley-Price, Paul, De Laurentiis, Michelino, Im, Young-Hyuck, Kuemmel, Sherko, El-Saghir, Nagi, O'Regan, Ruth, Gasch, Claudia, Solovieff, Nadia, Wang, Craig, Wang, Yongyu, Chakravartty, Arunava, Ji, Yan, and Tripathy, Debu

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Breast Cancer, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Breast Neoplasms, Female, Humans, Perimenopause, Purines, Receptor, ErbB-2, Receptors, Estrogen, Receptor, erbB-2, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeRibociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). The median OS was not reached in the ribociclib arm in the protocol-specified final analysis; we hence performed an exploratory OS and additional outcomes analysis with an extended follow-up (median, 53.5 months).Patients and methodsPatients were randomized to receive ET [goserelin plus nonsteroidal aromatase inhibitor (NSAI) or tamoxifen] with ribociclib or placebo. OS was evaluated with a stratified Cox proportional hazard model and summarized with Kaplan-Meier methods.ResultsThe intent-to-treat population included 672 patients. Median OS was 58.7 months with ribociclib versus 48.0 months with placebo [hazard ratio = 0.76; 95% confidence interval (CI), 0.61-0.96]. Kaplan-Meier estimated OS at 48 months was 60% and 50% with ribociclib and placebo, respectively. Subgroup analyses were generally consistent with the OS benefit, including patients who received NSAI and patients aged less than 40 years. Subsequent antineoplastic therapies following discontinuation were balanced between the ribociclib (77%) and placebo (78%) groups. Use of cyclin-dependent kinase 4/6 inhibitors after discontinuation was higher with placebo (26%) versus ribociclib (13%). Time to first chemotherapy was significantly delayed with ribociclib versus placebo. No drug-drug interactions were observed between ribociclib and either NSAI.ConclusionsRibociclib plus ET continued to show significantly longer OS than ET alone in pre-/perimenopausal patients, including patients aged less than 40 years, with HR+/HER2- ABC with 53.5 months of median follow-up (ClinicalTrials.gov, NCT02278120).

Published
2022

14. The Lancet Breast Cancer Commission

Author

Arreola-Ornelas, Hector, Bhadelia, Afsan, Boughey, Judy C, Chatterjee, Sanjoy, Dodwell, David, Doubova, Svetlana, Du Plooy, Dorothy, Essue, Beverley, Goel, Neha, Gralow, Julie, Hawley, Sarah, Kiely, Belinda, Mann, Ritse, Mertz, Shirley, Palmieri, Carlo, Poortmans, Philip, Spanic, Tanja, Stephen, Lesley, Symmans, Fraser, Towns, Catherine, Verhoeven, Didier, Vinnicombe, Sarah, Watkins, David, Yip, Cheng-Har, Zikmund-Fisher, Brian, Coles, Charlotte E, Earl, Helena, Anderson, Benjamin O, Barrios, Carlos H, Bienz, Maya, Bliss, Judith M, Cameron, David A, Cardoso, Fatima, Cui, Wanda, Francis, Prudence A, Jagsi, Reshma, Knaul, Felicia Marie, McIntosh, Stuart A, Phillips, Kelly-Anne, Radbruch, Lukas, Thompson, Mareike K, André, Fabrice, Abraham, Jean E, Bhattacharya, Indrani S, Franzoi, Maria Alice, Drewett, Lynsey, Fulton, Alexander, Kazmi, Farasat, Inbah Rajah, Dharrnesha, Mutebi, Miriam, Ng, Dianna, Ng, Szeyi, Olopade, Olufunmilayo I, Rosa, William E, Rubasingham, Jeffrey, Spence, Dingle, Stobart, Hilary, Vargas Enciso, Valentina, Vaz-Luis, Ines, and Villarreal-Garza, Cynthia

Published
2024
Full Text
View/download PDF

15. EUSOMA quality indicators for non-metastatic breast cancer: An update

Author

Rubio, Isabel T., Marotti, Lorenza, Biganzoli, Laura, Aristei, Cynthia, Athanasiou, Alexandra, Campbell, Christine, Cardoso, Fatima, Cardoso, Maria Joao, Coles, Charlotte E., Eicher, Manuela, Harbeck, Nadia, Karakatsanis, Andreas, Offersen, Birgitte V., Pijnappel, Ruud, Ponti, Antonio, Regitnig, Peter, Santini, Donatella, Sardanelli, Francesco, Spanic, Tanja, Varga, Zsuzsanna, Vrancken Peeters, Marie Jeanne T.F.D., Wengström, Yvonne, Wyld, Lynda, and Curigliano, Giuseppe

Published
2024
Full Text
View/download PDF

18. Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines

Author

Valencia, Fernando, Gómez, Henry L., Neciosup, Silvia P., Limón, Ronald, Torrico, María del Carmen, Morillas, Lena, Torres, Roberto, Sánchez, Cesar, Araya, Ingiborg, Gómez, Rodolfo, Bruges, Ricardo, Vargas, Carlos, Soria, Tannia, Muñoz, René, Riofrío, Mauricio, Gálvez, Marco, Ruiz, Rossana, Benites, Pilar, and Cardoso, Fatima

Published
2024
Full Text
View/download PDF

20. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups

Author

Pasquier, David, Bidaut, Luc, Oprea-Lager, Daniela Elena, deSouza, Nandita M, Krug, David, Collette, Laurence, Kunz, Wolfgang, Belkacemi, Yazid, Bau, Maria Grazia, Caramella, Caroline, De Geus-Oei, Lioe-Fee, De Caluwé, Alex, Deroose, Christophe, Gheysens, Olivier, Herrmann, Ken, Kindts, Isabelle, Kontos, Michalis, Kümmel, Sherko, Linderholm, Barbro, Lopci, Egesta, Meattini, Icro, Smeets, Ann, Kaidar-Person, Orit, Poortmans, Philip, Tsoutsou, Pelagia, Hajjaji, Nawale, Russell, Nicola, Senkus, Elżbieta, Talbot, Jean-Noël, Umutlu, Lale, Vandecaveye, Vincent, Verhoeff, Joost J C, van Oordt, Willemien Menke-van der Houven, Zacho, Helle D, Cardoso, Fatima, Fournier, Laure, Van Duijnhoven, Frederieke, and Lecouvet, Frédéric E

Published
2023
Full Text
View/download PDF

22. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Author

Delaloge, Suzette, Piccart, Martine, Rutgers, Emiel, Litière, Saskia, van 't Veer, Laura J, van den Berkmortel, Franchette, Brain, Etienne, Dudek-Peric, Aleksandra, Gil-Gil, Miguel, Gomez, Patricia, Hilbers, Florentine S, Khalil, Zaman, Knox, Susan, Kuemmel, Sherko, Kunz, Georg, Lesur, Anne, Pierga, Jean-Yves, Ravdin, Peter, Rubio, Isabel T, Saghatchian, Mahasti, Smilde, Tineke J, Thompson, Alastair M, Viale, Giuseppe, Zoppoli, Gabriele, Vuylsteke, Peter, Tryfonidis, Konstantinos, Poncet, Coralie, Bogaerts, Jan, and Cardoso, Fatima

Subjects
Genetics, Rare Diseases, Breast Cancer, Clinical Trials and Supportive Activities, Human Genome, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Docetaxel, Female, Humans, Middle Aged, Prospective Studies, MINDACT investigators and the TRANSBIG Consortium, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen.Patients and methodsR-C randomly assigned patients 1:1 between standard anthracycline-based regimens, with or without taxanes (control) and experimental docetaxel 75 mg/m2 intravenously plus oral capecitabine 825 mg/m2 two times per day for 14 days (DC) every 3 weeks for 6 cycles. The primary end point was disease-free survival (DFS). Secondary end points included overall survival and safety.ResultsOf 2,832 patients, 1,301 (45%) were randomly assigned, and 97% complied with R-C assignment. In the control arm, 29.6% only received taxanes (0.5% of N0 patients). DFS events (n = 148) were much less than required (n = 422) as a result of a lower-than-expected accrual and event rate. At 5 years of median follow-up, DFS was not different between DC (n = 652) and control (n = 649; 90.7% [95% CI, 88% to 92.8%] v 88.8% [95% CI, 85.9% to 91.1%]; hazard ratio [HR], 0.83 [95% CI, 0.60 to 1.15]; P = .26). Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and DFS in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms. DC led to more grade 1 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v 5.8%). Serious cardiac events occurred in 9 patients (control, n = 4; DC, n = 5). Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2 v 1). Five treatment-related deaths occurred (control, 2 [0.3%]; DC, 3 [0.5%]).ConclusionAlthough underpowered, this second randomization in MINDACT did not show any improvement in outcome or safety with the use of DC compared with anthracycline-based chemotherapy.

Published
2020

23. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

Author

Jacob, Laurent, Witteveen, Anke, Beumer, Inès, Delahaye, Leonie, Wehkamp, Diederik, van den Akker, Jeroen, Snel, Mireille, Chan, Bob, Floore, Arno, Bakx, Niels, Brink, Guido, Poncet, Coralie, Bogaerts, Jan, Delorenzi, Mauro, Piccart, Martine, Rutgers, Emiel, Cardoso, Fatima, Speed, Terence, van ’t Veer, Laura, and Glas, Annuska

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Clinical Trials and Supportive Activities, Cancer, Breast Cancer, Clinical Research, Biotechnology, Genetics, Adult, Aged, Biomarkers, Tumor, Breast Neoplasms, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Proteins, Prognosis, Protein Array Analysis, Randomized Controlled Trials as Topic, Transcriptome, Biological sciences, Biomedical and clinical sciences
Abstract

Gene expression data obtained in large studies hold great promises for discovering disease signatures or subtypes through data analysis. It is also prone to technical variation, whose removal is essential to avoid spurious discoveries. Because this variation is not always known and can be confounded with biological signals, its removal is a challenging task. Here we provide a step-wise procedure and comprehensive analysis of the MINDACT microarray dataset. The MINDACT trial enrolled 6693 breast cancer patients and prospectively validated the gene expression signature MammaPrint for outcome prediction. The study also yielded a full-transcriptome microarray for each tumor. We show for the first time in such a large dataset how technical variation can be removed while retaining expected biological signals. Because of its unprecedented size, we hope the resulting adjusted dataset will be an invaluable tool to discover or test gene expression signatures and to advance our understanding of breast cancer.

Published
2020

24. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Author

Braybrooke, Jeremy, Bradley, Rosie, Gray, Richard, Hills, Robert K, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Aihara, Tomohiko, Anderson, Stewart, Blum, Joanne, Cardoso, Fatima, Chen, Xiaosong, Crown, John P, Ejlertsen, Bent, Friedl, Thomas W P, Harbeck, Nadia, Janni, Wolfgang, Jensen, Maj-Britt, Mamounas, Eleftherios, Narui, Kazutaka, Nitz, Ulrike, Norton, Larry, O'Shaughnessy, Joyce, Piccart, Martine, Robert, Nicholas, Shao, Zhi-Ming, Slamon, Dennis, Sparano, Joseph, Watanabe, Toru, Yothers, Greg, Yu, Ke-Da, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Lui, Hui, Lui, Zulian, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Buzdar, Aman, Suman, Vera J, Hunt, Kelly K, Leonard, Robert C F, Mansi, Janine, Delbaldo, Catherine, Piedbois, Pascal, Quinaux, Emmanuel, Fesl, Christian, Gnant, Michael, Sölkner, Lidija, Steger, Guenther, Eikesdal, Hans Petter, Lønning, Per Eystein, Bee, Valerie, Fung, Helena, Mackey, John, Martin, Miguel, Press, Michael, De Azambuja, Evandro, Gelber, Richard, Regan, Meredith, Di Leo, Angelo, Van Dooren, Veerle, Nogaret, Jean Marie, Bartlett, John, Chen, Bingshu E, Gelmon, Karen, Goss, Paul E, Levine, Mark N, Parulekar, Wendy, Pritchard, Kathleen I, Shepherd, Lois, Berry, Donald, Cirrincione, Constance, Shulman, Lawrence N, Winer, Eric, Gelman, Rebecca S, Harris, Jay R, Henderson, Craig, Shapiro, Charles L, Christiansen, Peer, Ewertz, Marianne, Mouridsen, Henning T, Van Leeuwen, Elise, Linn, Sabine, Van Rossum, Annelot G J, Van Tinteren, Harm, Van Werkhoven, Erik, Goldstein, Lori, Gray, Robert, Eiermann, Wolfgang, Gianni, Luca, Valagussa, Pinuccia, Bogaerts, Jan, Bonnefoi, Herve, Poncet, Coralie, Huovinen, Riikka, Joensuu, Heikki, Bonneterre, Jacques, Fargeot, Pierre, Fumoleau, Pierre, Kerbrat, Pierre, Luporsi, Elisabeth, Namer, Moïse, Carrasco, Eva M, Segui, Miguel Angel, Meisner, Christoph, Loibl, Sibylle, Nekljudova, Valentina, Thomssen, Christoph, Von Minckwitz, Gunter, Kümmel, Sherko, Lopez, Massimo, Vici, Patrizia, Fountzilas, George, Koliou, Georgia, Mavroudis, Dimitrios, Saloustros, Emmanouil, Brain, Etienne, Delaloge, Suzette, Michiels, Stefan, Mathoulin-Pelissier, Simone, Bines, Jose, Sarmento, Roberta M B, Bonadonna, Gianni, Brambilla, Cristina, Rossi, Anna, Bliss, Judith, Coombes, Raoul Charles, Kilburn, Lucy, Marty, Michel, Amadori, Dino, Boccardo, Francesco, Nanni, Oriana, Rubagotti, Alessandra, Scarpi, Emanuela, Masuda, Norikazu, Toi, Masakazu, Ueno, Takayuki, Ishikawa, Takashi, Matsumoto, Koji, Takao, Shintaro, Sommer, Harald, Foroglou, Pericles, Giokas, George, Kondylis, D, Lissaios, Byron, Reinisch, Mattea, Lee, Keun Seok, Nam, Byung-Ho, Ro, Jung Sil, De Matteis, Andrea, Perrone, Francesco, Tang, Gong, Wolmark, Norman, Hozumi, Yasuo, Nomura, Yasuo, Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, De Mastro, Lucia, Venturini, Macro, Delozier, Thierry, Lemonnier, Jerome, Martin, Anne-Laure, Roché, Henri, Spielmann, Marc, Chen, Xiasong, Shen, Kunwei, Albain, Kathy, Barlow, William, Budd, George T, Gralow, Julie, Hayes, Dan, Bartlett-Lee, Peter, Ellis, Paul, Bianco, Angelo Raffaele, De Laurentiis, Michelino, De Placido, Sabino, Wildiers, Hans, Hsu, Limin, Eremin, Oleg, Walker, Leslie G, Ahlgren, Johan, Blomqvist, Carl, Holmberg, Lars, Lindman, Henrik, Asmar, Lina, Jones, Stephen E, Gluz, Oleg, Liedtke, Cornelia, Arriagada, Rodrigo, Bergsten-Nordström, Elizabeth, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Dignam, James, Dowsett, Mitch, Francis, Prudence A, Goetz, Matthew P, Goodwin, Pam, Halpin-Murphy, Pat, Hill, Catherine, Jagsi, Reshma, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Spanic, Tanja, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2023
Full Text
View/download PDF

25. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission

Author

Lawler, Mark, Davies, Lynne, Oberst, Simon, Oliver, Kathy, Eggermont, Alexander, Schmutz, Anna, La Vecchia, Carlo, Allemani, Claudia, Lievens, Yolande, Naredi, Peter, Cufer, Tanja, Aggarwal, Ajay, Aapro, Matti, Apostolidis, Kathi, Baird, Anne-Marie, Cardoso, Fatima, Charalambous, Andreas, Coleman, Michel P, Costa, Alberto, Crul, Mirjam, Dégi, Csaba L, Di Nicolantonio, Federica, Erdem, Sema, Geanta, Marius, Geissler, Jan, Jassem, Jacek, Jagielska, Beata, Jonsson, Bengt, Kelly, Daniel, Kelm, Olaf, Kolarova, Teodora, Kutluk, Tezer, Lewison, Grant, Meunier, Françoise, Pelouchova, Jana, Philip, Thierry, Price, Richard, Rau, Beate, Rubio, Isabel T, Selby, Peter, Južnič Sotlar, Maja, Spurrier-Bernard, Gilliosa, van Hoeve, Jolanda C, Vrdoljak, Eduard, Westerhuis, Willien, Wojciechowska, Urszula, and Sullivan, Richard

Published
2023
Full Text
View/download PDF

26. The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer

Author

Isnaldi, Edoardo, Richard, François, De Schepper, Maxim, Leduc, Sophia, Maetens, Marion, Geukens, Tatjana, Van Baelen, Karen, Nguyen, Ha-Linh, Rouas, Ghizlane, Zoppoli, Gabriele, Cardoso, Fatima, Sotiriou, Christos, Larsimont, Denis, Floris, Giuseppe, Biganzoli, Elia, and Desmedt, Christine

Published
2022
Full Text
View/download PDF

27. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.

Author

Dent, Rebecca, Cortés, Javier, Pusztai, Lajos, McArthur, Heather, Kümmel, Sherko, Bergh, Jonas, Denkert, Carsten, Park, Yeon Hee, Hui, Rina, Harbeck, Nadia, Takahashi, Masato, Untch, Michael, Fasching, Peter A, Cardoso, Fatima, Haiderali, Amin, Jia, Liyi, Nguyen, Allison Martin, Pan, Wilbur, O'Shaughnessy, Joyce, and Schmid, Peter

Subjects
TRIPLE-negative breast cancer, NEOADJUVANT chemotherapy, PHYSICAL mobility, PEMBROLIZUMAB, LEAST squares, TUMOR classification
Abstract

Background In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant pembrolizumab significantly improved pathological complete response and event-free survival vs neoadjuvant chemotherapy in early-stage triple-negative breast cancer (TNBC). We report patient-reported outcomes (PROs) from KEYNOTE-522. Methods Patients were randomized 2:1 to neoadjuvant pembrolizumab 200 mg or placebo every 3 weeks, plus 4 cycles of paclitaxel plus carboplatin and then 4 cycles of doxorubicin (or epirubicin) plus cyclophosphamide. After surgery, patients received adjuvant pembrolizumab or placebo for up to 9 cycles. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23) were prespecified secondary objectives. Between-group differences in least squares (LS) mean change from baseline (day 1 of cycle 1 in both neoadjuvant and adjuvant phases) to the prespecified latest time point with at least 60% completion and at least 80% compliance were assessed using a longitudinal model (no alpha error assigned). Results Week 21 (neoadjuvant phase) and week 24 (adjuvant phase) were the latest time points at which completion/compliance rates were ≥60%/80%. In the neoadjuvant phase, between-group differences (pembrolizumab plus chemotherapy [n = 762] vs placebo plus chemotherapy [n = 383]) in LS mean change from baseline to week 21 in QLQ-C30 global health status/quality of life (GHS/QoL), emotional functioning, and physical functioning were −1.04 (95% confidence interval = −3.46 to 1.38), −0.69 (95% CI = −3.13 to 1.75), and −2.85 (95% CI = −5.11 to −0.60), respectively. In the adjuvant phase, between-group differences (pembrolizumab [n = 539] vs placebo [n = 308]) in LS mean change from baseline to week 24 were −0.41 (95% CI = −2.60 to 1.77), −0.60 (95% CI = −2.99 to 1.79), and −1.57 (95% CI = −3.36 to 0.21). Conclusions No substantial differences in PRO assessments were observed between neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab vs neoadjuvant placebo plus chemotherapy in early-stage TNBC. Trial registration ClinicalTrials.gov, NCT03036488. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations.

Author

Elghazaly, Hesham, Azim, Hamdy A., Rugo, Hope S., Cameron, David, Swain, Sandra M., Curigliano, Giuseppe, Harbeck, Nadia, Tripathy, Debu, Arun, Banu, Aapro, Matti, Piccart, Martine, Cardoso, Fatima, Gligorov, Joseph, Elghazawy, Hagar, El Saghir, Nagi S., Penault‐Llorca, Frederique, Perez, Edith A., Poortmans, Philip, Abdelaziz, Hany, and El‐Zawahry, Heba M.

Subjects
CANCER hormone therapy, NEOADJUVANT chemotherapy, BREAST cancer, CANCER treatment, EXPERT evidence
Abstract

Background: The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the last few years, with the evolution of many controversial clinical situations that require consensus. Methods: During the 14th Breast‐Gynecological and Immuno‐Oncology International Cancer Conference held in Egypt in 2022, a panel of 44 BC experts from 13 countries voted on statements concerning debatable challenges in the neo/adjuvant treatment setting. The recommendations were subsequently updated based on the most recent data emerging. A modified Delphi approach was used to develop this consensus. A consensus was achieved when ≥75% of voters selected an answer. Results and Conclusions: The consensus recommendations addressed different escalation and de‐escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified. Consensus recommendations of the 14th Breast‐Gynecological and Immuno‐Oncology International Cancer Conference recapitulate the available clinical evidence and expert opinion to individualize and optimize the neoadjuvant therapy of breast cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. The Lancet Breast Cancer Commission

Author

Coles, Charlotte E, primary, Earl, Helena, additional, Anderson, Benjamin O, additional, Barrios, Carlos H, additional, Bienz, Maya, additional, Bliss, Judith M, additional, Cameron, David A, additional, Cardoso, Fatima, additional, Cui, Wanda, additional, Francis, Prudence A, additional, Jagsi, Reshma, additional, Knaul, Felicia Marie, additional, McIntosh, Stuart A, additional, Phillips, Kelly-Anne, additional, Radbruch, Lukas, additional, Thompson, Mareike K, additional, André, Fabrice, additional, Abraham, Jean E, additional, Bhattacharya, Indrani S, additional, Franzoi, Maria Alice, additional, Drewett, Lynsey, additional, Fulton, Alexander, additional, Kazmi, Farasat, additional, Inbah Rajah, Dharrnesha, additional, Mutebi, Miriam, additional, Ng, Dianna, additional, Ng, Szeyi, additional, Olopade, Olufunmilayo I, additional, Rosa, William E, additional, Rubasingham, Jeffrey, additional, Spence, Dingle, additional, Stobart, Hilary, additional, Vargas Enciso, Valentina, additional, Vaz-Luis, Ines, additional, Villarreal-Garza, Cynthia, additional, Arreola-Ornelas, Hector, additional, Bhadelia, Afsan, additional, Boughey, Judy C, additional, Chatterjee, Sanjoy, additional, Dodwell, David, additional, Doubova, Svetlana, additional, Du Plooy, Dorothy, additional, Essue, Beverley, additional, Goel, Neha, additional, Gralow, Julie, additional, Hawley, Sarah, additional, Kiely, Belinda, additional, Mann, Ritse, additional, Mertz, Shirley, additional, Palmieri, Carlo, additional, Poortmans, Philip, additional, Spanic, Tanja, additional, Stephen, Lesley, additional, Symmans, Fraser, additional, Towns, Catherine, additional, Verhoeven, Didier, additional, Vinnicombe, Sarah, additional, Watkins, David, additional, Yip, Cheng-Har, additional, and Zikmund-Fisher, Brian, additional

Published
2024
Full Text
View/download PDF

30. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature

Author

Alaeikhanehshir, Sena, primary, Ajayi, Taiwo, additional, Duijnhoven, Frederieke H., additional, Poncet, Coralie, additional, Olaniran, Ridwan O., additional, Lips, Esther H., additional, van 't Veer, Laura J., additional, Delaloge, Suzette, additional, Rubio, Isabel T., additional, Thompson, Alastair M., additional, Cardoso, Fatima, additional, Piccart, Martine, additional, and Rutgers, Emiel J.T., additional

Published
2024
Full Text
View/download PDF

31. Regularization Techniques in Radiomics: A Case Study on the Prediction of pCR in Breast Tumours and the Axilla

Author

Carrasquinha, Eunice, Santinha, João, Mongolin, Alexander, Lisitskiya, Maria, Ribeiro, Joana, Cardoso, Fátima, Matos, Celso, Vanneschi, Leonardo, Papanikolaou, Nickolas, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Cazzaniga, Paolo, editor, Besozzi, Daniela, editor, Merelli, Ivan, editor, and Manzoni, Luca, editor

Published
2020
Full Text
View/download PDF

33. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Curigliano, Giuseppe, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun-Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Poortmans, Philip, Prat, Aleix, Regan, Meredith, Rubio, Isabella, Rugo, Hope, Rutgers, Emiel, Sedlmayer, Felix, Semiglazov, Vladimir, Senn, Hans-Joerg, Shao, Zhiming, Spanic, Tanja, Tesarova, Petra, Thürlimann, Beat, Tjulandin, Sergei, Toi, Masakazu, Trudeau, Maureen, Turner, Nicholas, Vaz Luis, Inez, Viale, Giuseppe, Watanabe, Toru, Weber, Walter P., Winer, Eric P., Xu, Binghe, Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., Senn, H.J., Winer, E.P., and Gnant, M.

Published
2021
Full Text
View/download PDF

34. Breast cancer surgery with augmented reality

Author

Gouveia, Pedro F., Costa, Joana, Morgado, Pedro, Kates, Ronald, Pinto, David, Mavioso, Carlos, Anacleto, João, Martinho, Marta, Lopes, Daniel Simões, Ferreira, Arlindo R., Vavourakis, Vasileios, Hadjicharalambous, Myrianthi, Silva, Marco A., Papanikolaou, Nickolas, Alves, Celeste, Cardoso, Fatima, and Cardoso, Maria João

Published
2021
Full Text
View/download PDF

35. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Author

Piccart, Martine, van 't Veer, Laura J, Poncet, Coralie, Lopes Cardozo, Josephine M N, Delaloge, Suzette, Pierga, Jean-Yves, Vuylsteke, Peter, Brain, Etienne, Vrijaldenhoven, Suzan, Neijenhuis, Peter A, Causeret, Sylvian, Smilde, Tineke J, Viale, Giuseppe, Glas, Annuska M, Delorenzi, Mauro, Sotiriou, Christos, Rubio, Isabel T, Kümmel, Sherko, Zoppoli, Gabriele, Thompson, Alastair M, Matos, Erika, Zaman, Khalil, Hilbers, Florentine, Fumagalli, Debora, Ravdin, Peter, Knox, Susan, Tryfonidis, Konstantinos, Peric, Aleksandra, Meulemans, Bart, Bogaerts, Jan, Cardoso, Fatima, and Rutgers, Emiel J T

Published
2021
Full Text
View/download PDF

36. Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe

Author

Vrdoljak, Eduard, Gligorov, Joseph, Wierinck, Lieve, Conte, PierFranco, De Grève, Jacques, Meunier, Françoise, Palmieri, Carlo, Travado, Luzia, Walker, Andrew, Wiseman, Theresa, Wuerstlein, Rachel, Alba, Emilio, Biurrún, Concepción, D’Antona, Rosanna, Sola-Morales, Oriol, Ubaysi, Catherine, Ventura, Roberta, and Cardoso, Fatima

Published
2021
Full Text
View/download PDF

38. EUSOMA quality indicators for non-metastatic breast cancer: An update

Author

MS Radiologie, Cancer, Rubio, Isabel T, Marotti, Lorenza, Biganzoli, Laura, Aristei, Cynthia, Athanasiou, Alexandra, Campbell, Christine, Cardoso, Fatima, Cardoso, Maria Joao, Coles, Charlotte E, Eicher, Manuela, Harbeck, Nadia, Karakatsanis, Andreas, Offersen, Birgitte V, Pijnappel, Ruud, Ponti, Antonio, Regitnig, Peter, Santini, Donatella, Sardanelli, Francesco, Spanic, Tanja, Varga, Zsuzsanna, Vrancken Peeters, Marie Jeanne T F D, Wengström, Yvonne, Wyld, Lynda, Curigliano, Giuseppe, MS Radiologie, Cancer, Rubio, Isabel T, Marotti, Lorenza, Biganzoli, Laura, Aristei, Cynthia, Athanasiou, Alexandra, Campbell, Christine, Cardoso, Fatima, Cardoso, Maria Joao, Coles, Charlotte E, Eicher, Manuela, Harbeck, Nadia, Karakatsanis, Andreas, Offersen, Birgitte V, Pijnappel, Ruud, Ponti, Antonio, Regitnig, Peter, Santini, Donatella, Sardanelli, Francesco, Spanic, Tanja, Varga, Zsuzsanna, Vrancken Peeters, Marie Jeanne T F D, Wengström, Yvonne, Wyld, Lynda, and Curigliano, Giuseppe

Published
2024

39. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

Author

Aapro, Matti, Al-Ghazali, Hesham, Bachelot, Thomas, Barranger, Emmanuel, Berrada, Narjiss, Bidard, François-Clément, Bounedjar, Adda, Boussen, Hamouda, Campone, Mario, Cardoso, Fatima, Ceugnart, Luc, Classe, Jean-Marc, Cohen, Monique, Coutant, Charles, Cutuli, Bruno, Dalenc, Florence, Dieras, Véronique, Dohollou, Nadine, Giacchetti, Sylvie, Goncalves, Anthony, Freyer, Gilles, Hannoun-Levi, Jean-Michel, Hardy-Bessard, Anne-Claire, Jacquin, Jean-Philippe, Jacot, William, Kerrou, Khaldoun, Ladoire, Sylvain, Lerebours, Florence, Levy, Christelle, Llombart-Cussac, Antonio, Loirat, Delphine, Thomassin, Isabelle, Piccart, Martine, Petit, Thierry, Radosevic-Robin, Nina, Rotenberg, Luc, Rouzier, Roman, Salmon, Rémy, Vincent-Salomon, Anne, Spano, Jean-Philippe, Tallet, Agnès, Teixera, Luis, Tredan, Olivier, Verret, Benjamin, Zarca, Daniel, Zelek, Laurent, Zerbib, Eric, Gligorov, Joseph, Benderra, Marc-Antoine, Barthere, Xavier, de Forceville, Louise, Antoine, Eric Charles, Cottu, Paul Henri, Delaloge, Suzette, Pierga, Jean-Yves, Belkacemi, Yazid, Houvenaegel, Gilles, Pujol, Pascal, Rivera, Sofia, Spielmann, Marc, Penault-Llorca, Frédérique, and Namer, Moise

Published
2023
Full Text
View/download PDF

41. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Author

Vaz, Sofia C., Woll, John Patrick Pilkington, Cardoso, Fatima, Groheux, David, Cook, Gary J. R., Ulaner, Gary A., Jacene, Heather, Rubio, Isabel T., Schoones, Jan W., Peeters, Marie-Jeanne Vrancken, Poortmans, Philip, Mann, Ritse M., Graff, Stephanie L., Dibble, Elizabeth H., and de Geus-Oei, Lioe-Fee

Subjects
POSITRON emission tomography, BREAST cancer, LITERATURE reviews, NUCLEAR medicine
Abstract

Introduction: There is much literature about the role of 2-[18F]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject. Purpose: To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Methods: Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[18F]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria. Results: Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[18F]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[18F]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[18F]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[18F]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising. Conclusion: 2-[18F]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines.

Author

Groheux, David, Vaz, Sofia C., Ulaner, Gary A., Cook, Gary J. R., Woll, John Patrick Pilkington, Mann, Ritse M., Poortmans, Philip, Cardoso, Fatima, Jacene, Heather, Graff, Stephanie L., Rubio, Isabel T., Peeters, Marie-Jeanne Vrancken, Dibble, Elizabeth H., and de Geus-Oei, Lioe-Fee

Subjects
BREAST, POSITRON emission tomography, BREAST cancer, METASTATIC breast cancer
Abstract

This editorial commentary discusses the Joint EANM-SNMMI guidelines on the use of 2-[18F]FDG PET/CT in breast cancer. The guidelines provide updated information on the use of this imaging technique in various stages of breast cancer, such as initial staging, treatment response assessment, and recurrence assessment. The commentary compares these guidelines to those from ESMO and NCCN, highlighting both similarities and differences in their recommendations. The article emphasizes the importance of determining which patient subgroups would benefit from 2-[18F]FDG PET/CT, considering factors such as cost, radiation exposure, and potential false-positive results. It also calls for further research to support the use of this imaging technique and promote greater harmonization of imaging and clinical guidelines. [Extracted from the article]

Published
2024
Full Text
View/download PDF

43. Pneumocystis jirovecii Pneumonia Infection in Breast Cancer Receiving Dose-dense Chemotherapy: A Case Report and Literature Review.

Author

Mina, Alfred Patrick, Bonci, Eduard-Alexandru, Cardoso, Fatima, and Sousa, Berta

Subjects
EARLY medical intervention, BREAST tumors, COMPUTED tomography, ADJUVANT treatment of cancer, TREATMENT effectiveness, FEVER, CHEMORADIOTHERAPY, DOSE-effect relationship in pharmacology, CANCER chemotherapy, BRONCHOALVEOLAR lavage, PNEUMOCYSTIS pneumonia, CO-trimoxazole, COMBINED modality therapy, HORMONE therapy, CANCER fatigue, COUGH, ANTIBIOTIC prophylaxis
Abstract

We herein report 3 cases of breast cancer who developed Pneumocystis Jirovecii Pneumonia during dose-dense chemotherapy. The patients developed fever, fatigue, and cough on the 4th to 5th cycle of chemotherapy. Chest computed tomography (CT) scan showed ground-glass opacities, later on confirmed PCP as bronchoalveolar lavage (BAL) was performed. They were treated with Trimethoprim-Sulfamethoxazole (TMP-SMX) for 3 weeks, with clinical improvement. The first case was able to complete subsequent cycles of chemotherapy with TMP-SMX prophylaxis. The second case omitted the remaining cycles of chemotherapy and proceeded with adjuvant hormonal and radiotherapy. The third case also discontinued subsequent cycles and proceeded with surgery. All 3 cases didn't developed complications nor recurrence of infection on their subsequent treatments. Clinicians must be vigilant in recognizing those at risk for PCP especially among cancer patients undergoing dose-dense chemotherapy. Moreover, as the infection is life-threatening, early treatment must be initiated to prevent serious complications. Prophylactic antibiotic must be considered if there is a high-risk for recurrence of infection, thus preventing delay in surgery or adjuvant therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. The requirements of a specialist breast centre

Author

Biganzoli, Laura, Cardoso, Fatima, Beishon, Marc, Cameron, David, Cataliotti, Luigi, Coles, Charlotte E., Delgado Bolton, Roberto C., Trill, Maria Die, Erdem, Sema, Fjell, Maria, Geiss, Romain, Goossens, Mathijs, Kuhl, Christiane, Marotti, Lorenza, Naredi, Peter, Oberst, Simon, Palussière, Jean, Ponti, Antonio, Rosselli Del Turco, Marco, Rubio, Isabel T., Sapino, Anna, Senkus-Konefka, Elzbieta, Skelin, Marko, Sousa, Berta, Saarto, Tiina, Costa, Alberto, and Poortmans, Philip

Published
2020
Full Text
View/download PDF

49. Putting words into practice

Author

Decise, Donatella, Gheran, Mihaela Palade, Kimhi, Eti, Altmann-Pospischek, Claudia, Spitz, Sabine S., Casas, Ana, Haidinger, Renate, Calloud de Faudeur, Patricia, Elzayat, Mona, and Cardoso, Fatima

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results